Clinical Trials Logo

Alopecia clinical trials

View clinical trials related to Alopecia.

Filter by:

NCT ID: NCT05428449 Completed - Acne Vulgaris Clinical Trials

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne

NCT ID: NCT05368103 Completed - Alopecia Areata Clinical Trials

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Start date: April 27, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.

NCT ID: NCT05339958 Completed - Hair Thinning Clinical Trials

Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair

Start date: July 19, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning in men over the course of six months of continuous daily usage.

NCT ID: NCT05332743 Completed - Hair Thinning Clinical Trials

Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair

Start date: May 19, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of a vegan nutraceutical supplement with standardized botanicals in females leading a more plant-based lifestyle with self-perceived thinning hair

NCT ID: NCT05332366 Completed - Clinical trials for Frontal Fibrosing Alopecia

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This purpose of this trial is to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial will also investigate the clinical effect of delgocitinib cream on FFA compared to a placebo cream.

NCT ID: NCT05324293 Completed - Clinical trials for Androgenetic Alopecia

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.

NCT ID: NCT05296863 Completed - Clinical trials for Alopecia, Androgenetic

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Start date: October 11, 2021
Phase: Phase 3
Study type: Interventional

This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.

NCT ID: NCT05251831 Completed - Alopecia Areata Clinical Trials

Comparative Study Efficacy and Safety of of Activated Versus Non-Activated PRP

Start date: February 1, 2020
Phase: Early Phase 1
Study type: Interventional

This was comparative prospective study conducted on 40 subjects, diagnosed with alopecia areata of 40 the scalp, carried in a period from February 2020 and March 2021

NCT ID: NCT05244980 Completed - Clinical trials for Alopecia, Androgenetic

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

NCT ID: NCT05218642 Completed - Alopecia Clinical Trials

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Start date: January 31, 2022
Phase: Phase 2
Study type: Interventional

The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.